AI assistant
Quoin Pharmaceuticals, Ltd. — Director's Dealing 2024
Dec 27, 2024
35443_dirs_2024-12-27_a7177722-9e7e-4a3f-a720-66fe604d0d0c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2024-12-23
Reporting Person: Carter Denise P. (Director, Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-23 | Ordinary Shares | P | 555556 | $0.45 | Acquired | 602648 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-23 | Series F Warrants (right to buy) | $0.45 | P | 555556 | Acquired | 2026-12-23 | ADS (555556) | Direct |
| 2024-12-23 | Series G Warrants (right to buy) | $0.45 | P | 555556 | Acquired | 2029-12-24 | ADS (555556) | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
F2: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."
F3: The Warrants were exercisable immediately, subject to a beneficial ownership cap.